HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yu-Luan Chen Selected Research

SEP-363856

5/2022In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia.
1/2022A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yu-Luan Chen Research Topics

Disease

2Schizophrenia (Dementia Praecox)
05/2022 - 01/2022
1Neoplasms (Cancer)
11/2021
1Glioblastoma (Glioblastoma Multiforme)
11/2021
1Chronic Obstructive Pulmonary Disease (COPD)
06/2021
1Parkinson Disease (Parkinson's Disease)
10/2020

Drug/Important Bio-Agent (IBA)

2SEP-363856IBA
05/2022 - 01/2022
15-HT1A Serotonin ReceptorIBA
05/2022
1Serotonin 5-HT1 Receptor AgonistsIBA
05/2022
1Biomarkers (Surrogate Marker)IBA
11/2021
1HLA-A Antigens (HLA-A)IBA
11/2021
1WT1 ProteinsIBA
11/2021
1HLA Antigens (Human Leukocyte Antigens)IBA
11/2021
1EmulsionsIBA
11/2021
1VaccinesIBA
11/2021
1Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric
06/2021
1norapomorphineIBA
10/2020
1Sulfates (Sulfates, Inorganic)IBA
10/2020
1ApomorphineFDA Link
10/2020